0913693 B.C. Ltd. (REPCF)
OTCMKTS · Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
At close: Sep 14, 2026
0913693 B.C. Revenue
0913693 B.C. had revenue of 88.43K CAD in the quarter ending June 30, 2026. This brings the company's revenue in the last twelve months to 353.74K. In the year 2025, 0913693 B.C. had annual revenue of 353.74K.
Revenue
353.74K CAD
Revenue Growth
n/a
P/S Ratio
0.03
Revenue / Employee
353.74K CAD
Employees
1
Market Cap
7.36K USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 353.74K | -1.00 | - |
| Dec 31, 2024 | 353.74K | 1.00 | - |
| Dec 31, 2023 | 353.74K | - | - |
| Dec 31, 2022 | 353.74K | - | - |
| Dec 31, 2021 | 353.74K | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Aridis Pharmaceuticals | 22.36M |
| GeneLink | 1.58M |
| Theralink Technologies | 635.45K |
| Bioasis Technologies | 199.01K |
| Therapeutic Solutions International | 85.32K |
| Navidea Biopharmaceuticals | 610.00 |
0913693 B.C. News
- 3 years ago - RepliCel Provides Corporate Update - Accesswire
- 4 years ago - DermaPrecise(TM) Injection System Shown to Produce Consistently High Cell Count and Viability for Cell Therapy Injections - Accesswire
- 4 years ago - CORRECTION: Independent Laboratory Test Results Confirm Value of DermaPreciseTM Injection Consistency in Clinical Simulation Testing - Accesswire
- 4 years ago - Independent Laboratory Test Results Confirm Value of DermaPrecise (TM) Injection Consistency in Clinical Simulation Testing - Accesswire
- 4 years ago - RepliCel Announces Material Patent Milestones - Accesswire
- 4 years ago - RepliCel Closed Final Tranche of Strategic Investment Commitment - Accesswire
- 4 years ago - RepliCel Terminates License Agreement with Shiseido - Accesswire
- 4 years ago - RepliCel Ships DermaPrecise(TM) Injector Prototypes and Consumables to Independent Laboratory for Clinical Simulation Testing - Accesswire